• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Cystic Fibrosis Market Expected at $7.6 Billion by 2025


GlobalData, a research and consulting firm, announced that the cystic fibrosis market across key markets-US, France, Germany, Italy, Spain, UK, and Canada-is expected to increase more than triple from $2.1 billion in 2015 to about $7.6 billion by 2025, demonstrating a compound annual growth rate of 13.6%.

The company’s report explains that the driving force of the significant growth is from the introduction of Vertex’s Orkambi (ivacaftor + lumacaftor) in 2015, with the addition of introducing innovative, high-priced, disease-modifying cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

Although improvements of treatments for cystic fibrosis are in place, the lack of curative and mucolytic therapies, and the continuous fights against lung infection, indicate that patients still endure a substantial amount of unfulfilled needs.